---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-21-011129"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2021-08-10T23:59:59+00:00"
generated_at: "2026-06-29T16:22:30.054754+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Altimmune Q2 net loss $24.8M; ALT-801 Phase 1 data expected Sept 2021

## Summary
- Q2 net loss $24.8M ($0.60/shr) vs $16.8M ($0.94/shr) prior year; revenue $0.1M down from $0.7M.
- Cash, equivalents & investments $217.9M; raised $18.2M net via ATM in Q2.
- Recorded $8.1M impairment on construction-in-progress for terminated COVID-19 vaccine program.
- ALT-801 Phase 1 12-week data readout on three dose cohorts expected September 2021.
- IND for NASH on track for Q3 2021; obesity IND planned Q4 2021; Phase 2 trials targeted early 2022.

## SEC filing metadata
- accession: 0001558370-21-011129
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2021-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/0001558370-21-011129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000155837021011129/alt-20210810x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-21-011129
- JSON: https://secwatch.observer/filing/0001558370-21-011129.json
- Plain text: https://secwatch.observer/filing/0001558370-21-011129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.